Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Tumor characteristics of patients with recurrence after neoadjuvant ipi + nivo in melanoma

Judith Versluis • 10 Sep 2022
ESMO 2022
Melanoma Skin Cancer Ipilimumab Nivolumab

Judith Versluis, The Netherlands Cancer Institute, Amsterdam, Netherlands, discusses clinical features of acquired resistance in stage IV melanoma patients treated with immune checkpoint inhibition. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

More from Judith Versluis

1:39
OpACIN and OpACIN-neo: Neoadjuvant immunotherapy for advanced melanoma
Judith Versluis • 10 Sep 2022
2:43
Clinical & tumor characteristics of patients with recurrent melanoma upon immunotherapy
Judith Versluis • 12 Sep 2022

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals